Malaria: Confronting Challenges From Drug Discovery to Treatment

摘要 请求为题为疟疾：面对毒品挑战的Keystone研讨会提供支助 发现到治疗，由David Fidock博士、Kelly Chibale博士和Elizabeth Ashley博士组织。这次会议 将于2022年4月10日至13日在科罗拉多州的布雷肯里奇举行。 本次Keystone研讨会讨论了加快发展新的 可以治疗恶性疟原虫的抗疟疾药物，这些寄生虫已经对现有的第一批 一线毒品。这次会议的目的也是为了回顾抗疟疾药物发现的最新创新。 AS检查临床前和临床模型，以测试正在开发的化合物。该计划将探索 以青蒿素为基础的联合治疗(ACT)在不同流行环境下的疗效并讨论当前 减轻疾病负担的途径。将涵盖的其他主题包括对当前 抗疟疾耐药性的现状，包括机制研究以及它们如何促进我们对药物的理解 行动模式。最后，将讨论新药、预防、治疗和传播- 拦截策略。 这次会议将汇集药物发现和开发、药物机理研究方面的专家。 耐药的作用模式和机制，以及现场临床医生-研究人员和模型师更新 与会者就从药物发现到开发所需的多个方面进行了讨论。 参与者将了解ACT在该领域的疗效现状以及如何应对挑战 由抗疟疾耐药性的出现所造成的。这个论坛将允许科学家从事基础或应用研究 与现场研究人员和临床医生交流知识和想法。没有其他论坛可以 在这样一个集中的项目中解决了这一利基市场。最后，在这次会议上建立联系的机会 在这一点上对这个领域来说是无价的。预计参与者将发展新的合作，将 帮助推动这一领域向前发展，并克服这场对当前疟疾疗法的抵抗战。

ABSTRACT Support is requested for a Keystone Symposia conference entitled Malaria: Confronting Challenges From Drug Discovery to Treatment, organized by Drs. David Fidock, Kelly Chibale and Elizabeth Ashley. The conference will be held in Breckenridge, Colorado from April 10-13, 2022. This Keystone Symposia conference addresses the pressing need to accelerate the development of new antimalarials that can treat Plasmodium falciparum parasites, which have acquired resistance to existing first- line drugs. The conference is designed to review the recent innovations in antimalarial drug discovery, as well as examine preclinical and clinical models to test compounds in development. The program will explore the efficacy of artemisinin-based combination therapy (ACT) across different endemic settings and discuss current approaches to reducing the disease burden. Other topics that will be covered include a review of the current status of antimalarial resistance, including mechanistic studies and how they inform our understanding of drug modes of action. Finally, there will be discussions on new medicines, prophylaxis, treatment, and transmission- blocking strategies. This conference will bring together experts in drug discovery and development, mechanistic studies into drug modes of action and mechanisms of resistance, and field-based clinician-investigators and modelers to update attendees on the multiple aspects required to proceed from drug discovery through to development. Participants will learn about the current status of ACT efficacy in the field and how to respond to challenges posed by the emergence of antimalarial resistance. This forum will allow scientists in basic or applied research to exchange knowledge and ideas with field-based researchers and clinicians. There is no other forum which addresses this niche in such a concentrated program. Finally, the opportunity for networking at this conference is invaluable to the field at this point. It is anticipated that participants will develop new collaborations that will help drive the field forward and overcome this battle of resistance to current malaria therapeutics.